Viral Clearance Market to be Worth USD 2,644.2 Million by 2032; Increasing Demand for Biopharmaceuticals to Boost Market Growth

The global viral clearance market size was valued at USD 718.4 million in 2024. The market is projected to grow from USD 834.1 million in 2025 to USD 2,644.2 million by 2032, exhibiting a CAGR of 17.9% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, “Viral Clearance Market Size, Share & Industry Analysis, By Method (Viral Removal Method [Chromatography, Filtration, and Precipitation], Viral Inactivation Method [pH Modification, Solvent Detergent (S/D), Pasteurization, Dry Heat, and Others], and Viral Detection Method [Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In vivo Assay, In vitro assay, and Others]), By Application (Blood and Blood, Products, Recombinant Proteins, Cellular & Gene Therapy Products, Vaccines, and Others), By End-user (Pharmaceutical and Biotech Industry, Academic Research Institutes, CROs, and Others), and Regional Forecast, 2025-2032”.

The viral clearance studies are performed to ensure that the biopharmaceuticals are free from any contamination. The therapeutics obtained from animals, plants, or humans are at more risk for viral contamination. The increasing demand for viral clearance studies drives the market expansion due to the increasing demand for biopharmaceuticals.

The market witnessed slow growth during the COVID-19 pandemic as it witnessed decreased production capacity of the biotechnology and pharmaceutical companies globally. Moreover, COVID-19 lockdown restrictions were imposed to halt the virus spread, which hindered market expansion during the pandemic.

Charles River and PathoQuest SAS Partnered to Deliver Next-Generation Sequencing (NGS) to Clients

In December 2020, PathoQuest SAS and Charles River announced a collaboration in the U.S. The partnership will help Charles River deliver Next-Generation Sequencing (NGS) capabilities to clients in North America. The partnership is a part of the reliable, integrated, and convenient solution for the rapid viral safety testing of biological drugs and vaccines.

Rising Prevalence of Chronic Diseases to Drive Market Growth

The increasing prevalence of different chronic diseases, including cardiovascular diseases, diabetes, cancer, and others, drives the demand for these studies. The rising prevalence of these diseases increased the need to produce novel drugs for treatment, raising the focus of biotechnology and biopharmaceutical companies to develop new medications to treat these diseases. The increasing demand for viral clearance studies due to the rising focus of pharmaceutical companies on commercializing and developing biologically derived therapeutics to deliver effective treatment drives the viral clearance market growth.

However, the high costs associated with the technologies used to develop these studies hampers the market growth.

Rising Focus of Key Players Manufacturing Facility Expansion Drives Market Expansion

In terms of the competitive landscape, the market comprises key players, such as Charles River, Kedrion, and Others. These market players hold a significant viral clearance market share due to their strong focus on expanding their manufacturing facility to boost their service offerings and drive market growth. In November 2021, WuXi Biologics inaugurated its advanced therapies testing facility, featuring 140,000 square feet of laboratories. This expansion aims to triple the company's testing capacity, strengthening its CTDMO business model to better serve the growing demands of customers in the cell and gene therapy industry.

Notable Industry Development

• August 2021: WuXi Biologics launched a Biosafety Testing Center facility in Lin-gang, Shanghai. This launch has strengthened the company's service offerings and presence across China.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/viral-clearance-market-105611

List of the Companies Profiled in the Report:

• Merck KGaA (Germany)
• Charles River Laboratories (U.S.)
• WuXi Biologics (China)
• Texcell (France)
• Vironova (Sweden)
• Kedrion (Italy)
• Clean Cells (France)
• ViruSure GmbH (Austria)
• Sartorius AG (Germany)
• Syngene International Limited (India)
• Microbiologics (U.S.)

Further Report Findings:

• North America accounted for USD 268.7 million in 2024 and is expected to witness strong growth during the forecast period owing to the presence of national institutes that support life science research and biotechnology.
• Europe is expected to witness the second-highest market growth during the projected period due to the strong presence of biotechnology in Germany and France.
• The rising development and production of generics, medical research funding, and the large presence of CROs drive market expansion in Asia Pacific.

Table of Segmentation: